CureVac N.V. (CVAC)
- Previous Close
2.9700 - Open
3.0200 - Bid 3.0600 x 200
- Ask 3.1200 x 100
- Day's Range
3.0200 - 3.1450 - 52 Week Range
2.2150 - 12.3600 - Volume
341,374 - Avg. Volume
749,636 - Market Cap (intraday)
695.349M - Beta (5Y Monthly) 2.51
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2700 - Earnings Date May 21, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.90
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
www.curevac.comRecent News: CVAC
Performance Overview: CVAC
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CVAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CVAC
Valuation Measures
Market Cap
666.19M
Enterprise Value
274.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.31
Price/Book (mrq)
1.19
Enterprise Value/Revenue
4.28
Enterprise Value/EBITDA
-0.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.60%
Return on Equity (ttm)
-49.55%
Revenue (ttm)
53.76M
Net Income Avi to Common (ttm)
-260.17M
Diluted EPS (ttm)
-1.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
402.45M
Total Debt/Equity (mrq)
8.09%
Levered Free Cash Flow (ttm)
-151.51M
Research Analysis: CVAC
Company Insights: CVAC
CVAC does not have Company Insights